title: [Biomaterials and cell therapy in cartilage disorders].
abstract: Joint cartilage has a poor intrinsic ability to heal. Common surgical treatments for traumatic lesions, after debridement of the chondral defect, include stimulation of subchondral bone (microfracture), perichondrial or periosteal grafting, and mosaicplasty (osteochondral cylinder transplantation). Autologous chondrocyte transplantation (ACT) was the first application of cell therapy to orthopaedic surgery. Despite promising results, several groups have tested tissue engineering protocols based on ex vivo colonization of biodegradable polymer matrices that are subsequently transplanted to the target site. Tissue engineering as a treatment for osteoarthritis is even more challenging. Transplantation of genetically modified cells is an interesting concept, based on the production of therapeutic proteins directly at the target site.
authors: Institut de Biologie et Chimie des Protéines, UMR 5086 CNRS-UCB Lyon I, IFR 128 Biosciences Lyon-Gerland, 7 passage du Vercors, 69367 Lyon.
authors: Daniel
authors: D
authors: Herbage
authors: Hanane
authors: H
authors: Chajra
authors: Laurent
authors: L
authors: Galois
authors: Anne-Marie
authors: AM
authors: Freyria
authors: Frédéric
authors: F
authors: Mallein-Gerin
mesh_terms: D001672:Biocompatible Materials; D016025:Bone Transplantation; D002357:Cartilage Diseases / Q000601:surgery*; D002358:Cartilage, Articular / Q000293:injuries / Q000637:transplantation*; D019902:Chondrocytes / Q000378:metabolism / Q000637:transplantation*; D003646:Debridement; D006801:Humans; D010003:Osteoarthritis / Q000601:surgery*; D010641:Phenotype; D023822:Tissue Engineering; D014182:Transplantation, Autologous
chemical_list: D001672:Biocompatible Materials